IP Library Granted Patent US 8,007,752
Granted Patent B2
US 8,007,752 · App. 12/591,230 · Granted Aug 30, 2011

Process for preparing oral calcium compositions

Assignee: Nycomed Pharma As
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,007,752
App. No.
12/591,230
Granted
Aug 30, 2011
Kind
B2
Abstract

A process for the preparation of an orally administrable calcium composition comprising the steps of: (i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range of 3 to 40 μm, having a crystalline structure and having a surface area of 0.1 to 1.2 m 2 /g; (ii) mixing the calcium compound with a water-soluble diluent and an aqueous solution of a water soluble binder in a fluid bed granulation apparatus and dying the resulting mixture to produce a first granulate; (iii) optionally mixing the first granulate with one or more further components to produce a second granulate; and (iv) optionally compressing the first or second granulate to form tablets.

Claims (20)

1. A process for the preparation of an orally administrable calcium composition, said process comprising the steps of:

(i) obtaining a physiologically tolerable particulate calcium compound having a mean particle size in the range 3 to 40 μm, having a crystalline structure and having a surface area of 0.1 to 1.2 m 2 /g;

(ii) mixing said calcium compound with a water-soluble diluent and a water soluble binder in a fluid bed granulation apparatus and drying the resulting mixture to produce a first granulate, wherein said water-soluble diluent comprises at least one sweetener selected from the group consisting of sorbitol, xylitol, isomalt and mannitol, and wherein said first granulate has a particle size distribution of D(V,0.1=15-21 μm, D(V,0.5)=70-120 μm and D(V,0.9)=190-330 μm;

(iii) optionally mixing said first granulate with one or more further components to produce a second granulate; and

(iv) optionally compressing said first or second granulate to form tablets.

2. The process of claim 1 wherein said calcium compound is selected from the group consisting of calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate, calcium glucuronate, calcium aspartate, calcium glucoheptonate and mixtures of two or more thereof.

3. The process of claim 1 wherein said calcium compound is calcium carbonate.

4. The process of claim 1 wherein said calcium compound makes up 68 to 80% wt. of said first granulate.

5. The process of claim 1 wherein said calcium compound makes up 60 to 95% wt. of said second granulate.

6. The process of claim 1 wherein in step (i) the same material is used as said diluent and as said binder.

7. The process of claim 1 wherein said water-soluble diluent makes up 70 to 96% wt. of the total weight of said water-soluble diluent and said water-soluble binder in said first granulate.

8. The process of claim 1 wherein said water-soluble binder is selected from the group consisting of celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

9. The process of claim 1 wherein said water-soluble binder is a polyvinylpyrrolidone.

10. The process of claim 1 wherein said one or more further components are mixed with said first granulate, and wherein said one or more further components are selected from the group consisting of vitamin B 6 , vitamin K, vitamin C, vitamin D, isoflavones, inulin, oligofructose and mixtures of two or more thereof.

11. The process of claim 1 wherein in step (ii) said calcium compound is also mixed with isoflavones.

12. A granulate comprising a fluid bed granulation granulate product of a physiologically tolerable calcium compound, a water-soluble binder and a water-soluble diluent, wherein said calcium compound has a mean particle size in the range 3 to 40 μm, has a crystalline structure and has a surface area of 0.1 to 1.2 m 2 /g; wherein said water-soluble diluent comprises at least one sweetener selected from the group consisting of sorbitol, xylitol, isomalt and mannitol, and wherein said granulate has a particle size distribution of D(V,0.1=15-21 μm, D(V,0.5)=70-120 μm and D(V,0.9)=190-330 μm.

13. The granulate of claim 12 wherein said granulate further comprises a lubricant.

14. The granulate of claim 12 wherein said calcium compound is selected from the group consisting of calcium carbonate, calcium lactate, calcium gluconate, calcium citrate, calcium glycerophosphate, calcium phosphate, calcium hydrogen phosphate, calcium glucuronate, calcium aspartate, calcium glucoheptonate and mixtures of two or more thereof.

15. The granulate of claim 12 wherein said water-soluble binder is selected from the group consisting of celluloses, polysaccharides, maltodextrin, inulin and polyvinylpyrrolidone.

16. The granulate of claim 12 wherein said granulate further comprises a component selected from the group consisting of vitamin B 6 , vitamin K, vitamin C, vitamin D, isoflavones, inulin, oligofructose and mixtures of two or more thereof.

Assignments (3)
CHANGE OF NAME Recorded Jan 16, 2018
From: TAKEDA NYCOMED AS
To: TAKEDA AS
Reel/Frame 045075/0149 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 030601 FRAME 0758. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE SHOULD BE LISTED AS: TAKEDA NYCOMED AS. Recorded Jul 9, 2013
From: NYCOMED PHARMA AS
To: TAKEDA NYCOMED AS
Reel/Frame 030910/0420 →
CHANGE OF NAME Recorded Jun 12, 2013
From: NYCOMED PHARMA AS
To: TAKEDA NYCOMB AS
Reel/Frame 030601/0758 →
Priority Claims (1)
GB 9825033.5 · Nov 13, 1998 · national
Continuity (5)
Continuation 11798519 · May 15, 2007
Continuation 10973352 · Oct 27, 2004
Continuation 09831553 · Nov 5, 2001
Continuation In Part PCTGB9903666 · Nov 5, 1999
Related Publication 20100119621A1 · May 13, 2010